Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008

Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
PRINCETON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX)
is scheduled to announce its 2007 fourth quarter and year-end results on Tuesday,
February 26, 2008 by press release after the financial markets close.

    Following the release, Medarex's management will host a conference call and live
webcast at 4:30 p.m. Eastern Time. To access the call live, please dial
1-866-510-0710 (U.S./Canada) or 1-617-597-5378 (international) and enter passcode
number 15176024. The webcast can be accessed through the Investor Relations section
of Medarex's website at www.medarex.com and will be archived for 14 days following
the webcast.

    A telephonic replay of the conference call will be available until midnight
Eastern Time, March 4, 2008. Access numbers for this replay are 1-888-286-8010
(U.S./Canada) or 1-617-801-6888 (international); passcode number 75836084.

    About Medarex

    Medarex is a biopharmaceutical company focused on the discovery, development and
potential commercialization of fully human antibody-based therapeutics to treat
life-threatening and debilitating diseases, including cancer, inflammation,
autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R)
technology and product development and clinical manufacturing experience to
generate, support and potentially commercialize a broad range of fully human
antibody product candidates for itself and its partners. Over thirty of these
therapeutic product candidates derived from Medarex technology are in human clinical
testing or have had INDs submitted for such trials, with seven of the most advanced
product candidates currently in Phase 3 clinical trials. Medarex is committed to
building value by developing a diverse pipeline of antibody products to address the
world's unmet healthcare needs. For more information about Medarex, visit its
website at www.medarex.com.

    Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of
Medarex, Inc. All rights are reserved.

SOURCE  Medarex, Inc.
    -0-                             02/20/2008
    /CONTACT:  Christian S. Schade, Senior VP and CFO, +1-609-430-2880, Laura S.
Choi, Investor Relations, +1-609-430-2880, ext. 2216, or Jean Mantuano, Corporate
Communications (media), +1-609-430-2880, ext. 2221, all of Medarex, Inc./
    /Company News On-Call:  http://www.prnewswire.com/comp/108265.html /
    /Web site:  http://www.medarex.com /
    (MEDX)

CO:  Medarex, Inc. ST:  New Jersey IN:  BIO MTC HEA SU:  CCA

KS-KG -- NEW124 -- 8493 02/20/2008 16:09 EST http://www.prnewswire.com